Press Releases

• July 26, 2018
  

  First-ever biomarker qualified for Parkinson’s is a vital step toward improved clinical trials

  FOR IMMEDIATE RELEASE Contact: Kissy Black 615.298.1144 [email protected]   Tucson, AZ — July 26, 2018 – The Critical Path Institute’s (C-Path) Critical Path for Parkinson’s Consortium (CPP), in partnership with Parkinson’s UK, announces that the European Medicines Agency (EMA) has issued a positive qualification opinion on an imaging test (biomarker) as a tool to enrich...
• May 7, 2018
  

  C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)

  TUCSON, Ariz. – May 7, 2018 — Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its second clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA). The qualification of the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) for exploratory use represents another major milestone for the PRO Consortium and, specifically,...
• April 16, 2018
  Helmsley Charitable Trust Awards Critical Path Institute a Grant to Focus on Crohn’s Disease Biomarkers

  Tucson, AZ, and New York, NY – April 16, 2018 — The Leona M. and Harry B. Helmsley Charitable Trust has awarded Critical Path Institute (C-Path) a grant to support a Crohn’s disease biomarker pre-consortium. The pre-consortium will identify unmet needs for the use of biomarkers in developing new treatments for people with Crohn’s disease. Currently,...
• March 28, 2018
  

  C-Path and CHDI launch consortium to accelerate development of Huntington’s disease therapies

        Tucson, AZ, and New York, NY – March 28, 2018 – The Critical Path Institute (C-Path), together with CHDI Foundation, Inc. (CHDI), today announced the official launch of C-Path’s Huntington’s Disease Regulatory Science Consortium (HD-RSC). In addition to these cofounders, the consortium also includes more than 20 different member organizations, including industry partners,...
• March 24, 2018
  

  Global Health Partners Accelerate Uptake of Genetic Sequencing for Surveillance And Diagnosis Of Drug-Resistant Tuberculosis

        WHO adopts ReSeqTB as bioinformatics platform for TB surveillance, enabling the global scale-up of culture-free, drug-resistant Mycobacterium tuberculosis surveillance programs based on sequencing technologies Renewed funding from the Bill & Melinda Gates Foundation has been applied for to support FIND, C-Path, and WHO to take ReSeqTB to the next level as part...